Structure Database (LMSD)

LM_ID Common Name Systematic Name Main class Sub class Mass Formula
LMSP0502AE01 SSEA-3 antigen(d18:1/16:0) Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/16:0) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1388.8 C66H120N2O28
LMSP0502AE02 SSEA-3 antigen(d18:1/18:0) Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/18:0) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1416.83 C68H124N2O28
LMSP0502AE03 SSEA-3 antigen(d18:1/20:0) Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/20:0) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1444.87 C70H128N2O28
LMSP0502AE04 SSEA-3 antigen(d18:1/22:0) Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/22:0) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1472.9 C72H132N2O28
LMSP0502AE05 SSEA-3 antigen(d18:1/24:0) Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:0) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1500.93 C74H136N2O28
LMSP0502AE07 SSEA-3 antigen(d18:1/24:1(15Z)) Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z)) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1498.91 C74H134N2O28
LMSP0502AE06 SSEA-3 antigen(d18:1/26:0) Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/26:0) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1528.96 C76H140N2O28
LMSP0502AE08 SSEA-3 antigen(d18:1/26:1(17Z)) Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z)) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1526.94 C76H138N2O28
LMSP0502AH01 globo-Lex-9(d18:1/16:0) Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-6(Galbeta1-3)GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/16:0) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1899.99 C86H153N3O42
LMSP0502AH02 globo-Lex-9(d18:1/18:0) Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-6(Galbeta1-3)GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/18:0) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1928.02 C88H157N3O42
LMSP0502AH03 globo-Lex-9(d18:1/20:0) Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-6(Galbeta1-3)GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/20:0) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1956.06 C90H161N3O42
LMSP0502AH04 globo-Lex-9(d18:1/22:0) Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-6(Galbeta1-3)GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/22:0) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1984.09 C92H165N3O42
LMSP0502AH05 globo-Lex-9(d18:1/24:0) Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-6(Galbeta1-3)GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:0) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 2012.12 C94H169N3O42
LMSP0502AH07 globo-Lex-9(d18:1/24:1(15Z)) Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-6(Galbeta1-3)GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z)) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 2010.1 C94H167N3O42
LMSP0502AH06 globo-Lex-9(d18:1/26:0) Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-6(Galbeta1-3)GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/26:0) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 2040.15 C96H173N3O42
LMSP0502AH08 globo-Lex-9(d18:1/26:1(17Z)) Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-6(Galbeta1-3)GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z)) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 2038.13 C96H171N3O42
LMSP0502AJ01 type IV A antigen(d18:1/16:0) GalNAcalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/16:0) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1737.94 C80H143N3O37
LMSP0502AJ02 type IV A antigen(d18:1/18:0) GalNAcalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/18:0) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1765.97 C82H147N3O37
LMSP0502AJ03 type IV A antigen(d18:1/20:0) GalNAcalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/20:0) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1794 C84H151N3O37
LMSP0502AJ04 type IV A antigen(d18:1/22:0) GalNAcalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/22:0) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1822.03 C86H155N3O37
LMSP0502AJ05 type IV A antigen(d18:1/24:0) GalNAcalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:0) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1850.07 C88H159N3O37
LMSP0502AJ07 type IV A antigen(d18:1/24:1(15Z)) GalNAcalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z)) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1848.05 C88H157N3O37
LMSP0502AJ06 type IV A antigen(d18:1/26:0) GalNAcalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/26:0) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1878.1 C90H163N3O37
LMSP0502AJ08 type IV A antigen(d18:1/26:1(17Z)) GalNAcalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z)) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1876.08 C90H161N3O37
LMSP0502AK01 type IV B antigen(d18:1/16:0) Galalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/16:0) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1696.91 C78H140N2O37
LMSP0502AK02 type IV B antigen(d18:1/18:0) Galalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/18:0) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1724.94 C80H144N2O37
LMSP0502AK03 type IV B antigen(d18:1/20:0) Galalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/20:0) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1752.98 C82H148N2O37
LMSP0502AK04 type IV B antigen(d18:1/22:0) Galalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/22:0) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1781.01 C84H152N2O37
LMSP0502AK05 type IV B antigen(d18:1/24:0) Galalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:0) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1809.04 C86H156N2O37
LMSP0502AK07 type IV B antigen(d18:1/24:1(15Z)) Galalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z)) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1807.02 C86H154N2O37
LMSP0502AK06 type IV B antigen(d18:1/26:0) Galalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/26:0) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1837.07 C88H160N2O37
LMSP0502AK08 type IV B antigen(d18:1/26:1(17Z)) Galalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z)) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1835.05 C88H158N2O37
LMSP0502AI01 type IV H(d18:1/16:0) Fucalpha1-2Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/16:0) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1534.86 C72H130N2O32
LMSP0502AI02 type IV H(d18:1/18:0) Fucalpha1-2Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/18:0) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1562.89 C74H134N2O32
LMSP0502AI03 type IV H(d18:1/20:0) Fucalpha1-2Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/20:0) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1590.92 C76H138N2O32
LMSP0502AI04 type IV H(d18:1/22:0) Fucalpha1-2Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/22:0) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1618.95 C78H142N2O32
LMSP0502AI05 type IV H(d18:1/24:0) Fucalpha1-2Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:0) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1646.99 C80H146N2O32
LMSP0502AI07 type IV H(d18:1/24:1(15Z)) Fucalpha1-2Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z)) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1644.97 C80H144N2O32
LMSP0502AI06 type IV H(d18:1/26:0) Fucalpha1-2Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/26:0) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1675.02 C82H150N2O32
LMSP0502AI08 type IV H(d18:1/26:1(17Z)) Fucalpha1-2Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z)) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1673 C82H148N2O32
LMSP0502BK03 Galbeta1-3GalNAcbeta1-4Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/20:0) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1444.87 C70H128N2O28
LMSP0502AV04 GalNAcalpha1-3GalNAcbeta1-3(Fucalpha1-2Galbeta1-3GalNAcbeta1-4)Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/22:0) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 2025.11 C94H168N4O42
LMSP0502BI02 Fucalpha2-3(Galbeta1-4)GlcNAcbeta1-6GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/18:0) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1765.97 C82H147N3O37
LMSP0502AX07 GalNAcbeta1-3Galalpha1-3Galalpha1-3Galalpha1-3Galalpha1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z)) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1985.07 C92H164N2O43
LMSP0502AS06 GlcNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/26:0) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1366.91 C70H130N2O23
LMSP0502BK07 Galbeta1-3GalNAcbeta1-4Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z)) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1498.91 C74H134N2O28
LMSP0502AQ06 GalNAcbeta1-3Galalpha1-3Galalpha1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/26:0) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1691.01 C82H150N2O33
LMSP0502BB04 GalNAcalpha1-3GalNAcbeta1-3(GalNAcbeta1-4)Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/22:0) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1717 C82H148N4O33
LMSP0502BN02 GalNAcbeta1-3(Fucalpha2-3Galbeta1-3GalNAcbeta1-4)Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/18:0) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1765.97 C82H147N3O37
LMSP0502BN08 GalNAcbeta1-3(Fucalpha2-3Galbeta1-3GalNAcbeta1-4)Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z)) Neutral glycosphingolipids [SP05] Galalpha1-4Galbeta1-4Glc- (Globo series) [SP0502] 1876.08 C90H161N3O37